PTC Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on PTC Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how PTC Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with PTC Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
PTC Therapeutics Inc (PTC) is a biopharmaceutical company that discovers, develops, and commercializes medicines for rare diseases related to therapy areas of Metabolism and Neurology. Its major products include ataluren and deflazacort for the treatment of Duchenne muscular dystrophy (DMD); eladocagene exuparvovec or eladocagene exuparvovec-tneq for the treatment of Aromatic L-amino decarboxylase (AADC); inotersen and volanesorsen for the treatment of stage 1 or stage 2 polyneuropathy in an adult patient; and risdiplam for the treatment of spinal muscular atrophy (SMA). PTC also offers the usage of the Splicing platform for modulating splicing to control protein production and the inflammation and ferroptosis platform to target oxidative stress and inflammation pathways to treat CNS diseases. The company offers its products to customers through brands Translarna, Emflaza, Upstaza, Kebilidi, Tegsedi, Waylivra, and Evrysdi. It collaborates with channel partners and distribution networks to facilitate the global commercialization of its products in the Americas, Africa, Europe, and Asia. PTC is headquartered in South Plainfield, New Jersey, the US.
Headquarters
United States of America
Address
500 Warren Corporate Center Drive, New Jersey, 07059
Website
https://www.ptcbio.com/
Telephone
1 908 2227000
No of Employees
991
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTCT (NASD)
Revenue (2024)
$1.7B
114.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
287.9%
(2024 vs 2023)
Market Cap*
$6.5B
Net Profit Margin (2024)
XYZ
187.6%
(2024 vs 2023)
* As of and is in US$
PTC Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Ataluren: Duchenne Muscular Dystrophy | Translarna |
| Deflazacort: Duchenne Muscular Dystrophy | Emflaza |
| Eladocagene Exuparvovec: Aromatic L-Amino Decarboxylase | Upstaza |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In December, the company received regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for Sephience(sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU). |
| 2025 | Regulatory Approval | In June, the company received marketing approval from the European Commission for Sephience to treat children and adults living with Phenylketonuria (PKU). |
| 2025 | Regulatory Approval | In February, the company received new drug filing approval from the US FDA for vatiquinone to treat children and adults living with Friedreich's ataxia (FA). |
Competitor Comparison
| Key Parameters | PTC Therapeutics Inc | Pfizer Inc | Astellas Pharma Inc | Daiichi Sankyo Co Ltd | Biogen Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Japan | Japan | United States of America |
| City | Warren | New York City | Chuo-Ku | Chuo-Ku | Cambridge |
| State/Province | New Jersey | New York | Tokyo | Tokyo | Massachusetts |
| No. of Employees | 991 | 75,000 | 13,643 | 20,171 | 7,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Schmertzler | Chairman | Executive Board | 2004 | 74 |
| Matthew B. Klein, MD | Director; Chief Executive Officer | Executive Board | 2023 | 54 |
| Pierre Gravier | Chief Financial Officer | Senior Management | 2023 | 41 |
| Christine Utter | Head - People Services; Chief Accounting Officer; Senior Vice President | Senior Management | 2019 | 48 |
| Linda Montella-Carter | Chief Information Officer; Senior Vice President | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer